Investors & Media
Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference
Information on the presentation is as follows:
|Event:||30th Annual ROTH Conference|
|Date:||Monday, March 12, 2018|
|Time:||8:30 am PDT|
|Location:||Salon 6, Ritz Carlton, Laguna Niguel|
A live webcast of the presentation will be available through the Company's website: www.cyclacel.com. The webcast will be archived for 90 days.
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the
|Company:||Paul McBarron, (908) 517-7330, email@example.com|
|Investor Relations:||Russo Partners LLC, Alexander Fudukidis, (646) 942-5632,|
© Copyright 2018 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.